Recent research have centered on the overlap of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopaminergic communication. While GCGR agonists are increasingly employed for managing type 2 diabetes mellitus, their potential effects on reinforcement circuits, specifically governed by dopaminergic networks,